JP2005516044A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516044A5
JP2005516044A5 JP2003563468A JP2003563468A JP2005516044A5 JP 2005516044 A5 JP2005516044 A5 JP 2005516044A5 JP 2003563468 A JP2003563468 A JP 2003563468A JP 2003563468 A JP2003563468 A JP 2003563468A JP 2005516044 A5 JP2005516044 A5 JP 2005516044A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
composition
medicament
staphylococcal
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003563468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516044A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/040925 external-priority patent/WO2003063772A2/en
Publication of JP2005516044A publication Critical patent/JP2005516044A/ja
Publication of JP2005516044A5 publication Critical patent/JP2005516044A5/ja
Pending legal-status Critical Current

Links

JP2003563468A 2001-12-21 2002-12-23 モノクローナル抗体の鼻内投与によるブドウ球菌の鼻コロニー形成を阻止又は緩和する方法 Pending JP2005516044A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34180601P 2001-12-21 2001-12-21
PCT/US2002/040925 WO2003063772A2 (en) 2001-12-21 2002-12-23 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies

Publications (2)

Publication Number Publication Date
JP2005516044A JP2005516044A (ja) 2005-06-02
JP2005516044A5 true JP2005516044A5 (https=) 2006-03-02

Family

ID=27662943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003563468A Pending JP2005516044A (ja) 2001-12-21 2002-12-23 モノクローナル抗体の鼻内投与によるブドウ球菌の鼻コロニー形成を阻止又は緩和する方法

Country Status (5)

Country Link
US (1) US20030224000A1 (https=)
EP (1) EP1465926A4 (https=)
JP (1) JP2005516044A (https=)
CA (1) CA2469571A1 (https=)
WO (1) WO2003063772A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20050050659A1 (en) 2003-09-09 2005-03-10 The Procter & Gamble Company Electric toothbrush comprising an electrically powered element
WO2005072778A2 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
WO2007024852A2 (en) * 2005-08-22 2007-03-01 Biosynexus Incorporated Methods for testing vaccine candidates against bacterial infection in rodents
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009137677A2 (en) * 2008-05-07 2009-11-12 Innovative Biosensors, Inc. Reagents, methods, and systems for detecting methicillin-resistant staphylococcus
CA2746330C (en) * 2008-12-23 2017-08-29 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
US20100260752A1 (en) * 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
JP5816170B2 (ja) * 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
WO2011017791A1 (pt) * 2009-08-10 2011-02-17 Fundação Oswaldo Cruz Anticorpos monoclonais para a proteína pbp2-a e sequências homólogas para o tratamento de infeçcões e imunodiagnóstico em bactérias do filo firmicutes
WO2011035158A2 (en) 2009-09-17 2011-03-24 Guthery B Eugene Nasal, wound and skin formulations and methods for control of antibiotic-resistant staphylococci and other gram-positive bacteria
MX2012006961A (es) 2009-12-17 2012-10-03 Fina Biosolutions Llc Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
DK2560738T3 (da) 2010-04-23 2019-08-26 Serum Inst India Ltd Simpel fremgangsmåde til samtidig fjernelse af flere urenheder fra dyrkningssupernatanter til ultralave niveauer
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
WO2013096948A1 (en) * 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
EP2872535A1 (en) 2012-07-16 2015-05-20 Pfizer Inc. Saccharides and uses thereof
US9434977B2 (en) * 2013-02-27 2016-09-06 Avent, Inc. Rapid identification of organisms in bodily fluids
WO2014142117A1 (ja) 2013-03-12 2014-09-18 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
BR112021005522A2 (pt) * 2018-11-21 2021-06-29 Regeneron Pharmaceuticals, Inc. anticorpo isolado ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, métodos de prevenção, tratamento ou melhoria de infecção por s. aureus, uma condição causada por infecção por s. aureus, ou pelo menos um sintoma de infecção por s. aureus, ou de diminuir a frequência ou gravidade de infecção por s. aureus, uma condição causada por infecção por s. aureus, de pelo menos um sintoma de infecção por s. aureus, para prevenir uma infecção por s. aureus, de prevenção, tratamento ou melhoria de infecção por s. aureus, ou de diminuir a frequência ou gravidade de infecção por s. aureus, em um indivíduo com um cateter, uma articulação protética ou qualquer outro objeto estranho, para prevenir, tratar ou melhorar a infecção estafilocócica, ou para diminuir a frequência ou gravidade da infecção estafilócica
US11440952B2 (en) 2020-10-16 2022-09-13 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
US20220280679A1 (en) * 2021-03-08 2022-09-08 Innovation Chemical and Enviromental Technologies, Inc. Prophylactic Gel Compositions and Use as Barriers to Bacterial and Viral Colonization
WO2023201306A1 (en) * 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
CA3256035A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5681565A (en) * 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
JP2003503015A (ja) * 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions

Similar Documents

Publication Publication Date Title
JP2005516044A5 (https=)
JP2006513139A5 (https=)
US12491245B2 (en) Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US20100166772A1 (en) ANTIGEN-BINDING PROTEINS TARGETING S. AUREUS ORF0657n
EP2464665B1 (en) Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation
JP2005516044A (ja) モノクローナル抗体の鼻内投与によるブドウ球菌の鼻コロニー形成を阻止又は緩和する方法
JP2011521662A5 (https=)
JP2005519619A5 (https=)
JP2021050210A (ja) 免疫グロブリンの噴霧化
CN102695724B (zh) 指向金黄葡萄球菌表位isaa或isab的抗体或其片段
KR20210126641A (ko) 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
US10639370B2 (en) Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP2003531866A (ja) 抗体を用いた呼吸器疾患の組合せ治療法
EP4286409A1 (en) Antigen-binding protein targeting staphylococcus aureus ?-hemolysis and application thereof
CA2469714A1 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
JP2025518050A (ja) 吸入可能治療薬のための組成物および方法
Panina et al. Recombinant antibodies to the Ebola virus glycoprotein
CN117679507A (zh) IgM抗体及其应用
JPWO2022103700A5 (https=)
HK1237800A1 (en) Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
HK1237800B (zh) 可用於被动流感免疫的抗体及其组合物、组合和使用方法
WO2010077473A2 (en) Monoclonal antibodies that react with the capsule of bacillus anthracis